Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
29 hedge funds and large institutions have $12M invested in Hepion Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.
1,515% more capital invested
Capital invested by funds: $741K → $12M (+$11.2M)
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
142% more funds holding
Funds holding: 12 → 29 (+17)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
17% more call options, than puts
Call options by funds: $657K | Put options by funds: $562K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.48M |
| 2 |
BlackRock
New York
|
+$2.94M |
| 3 |
Renaissance Technologies
New York
|
+$853K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$606K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$485K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$148K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$85.5K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$48K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$36K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$23.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $8K | +$2.59K | +1 | +33% |
|
|
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $7.67K | +$10.4K | +4 | New |
|
28
UBS Group
Zurich,
Switzerland
| $1K | -$2.59K | -1 | -50% |
|
|
VFA
29
Valeo Financial Advisors
Carmel,
Indiana
| $1K | +$2.59K | +1 | New |
|
|
SM
30
Sabby Management
Miami Beach,
Florida
| – | -$148K | -57 | Closed |
|
|
31
Bank of America
Charlotte,
North Carolina
| – | -$85.5K | -33 | Closed |
|
32
Millennium Management
New York
| – | -$91 | -29 | Closed |
|
|
SFI
33
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$48K | -16 | Closed |
|
|
ECM
34
ExodusPoint Capital Management
New York
| – | -$36K | -12 | Closed |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| – | -$14K | -5 | Closed |
|
HEPA Hedge Fund Activity: Q4 2020 in Review
29 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2020, worth a combined $12M — up 1,515% from $741K a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new HEPA positions and 6 closed out — a net gain of 17 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $4.48M. The largest seller was Sabby Management, exiting entirely with an estimated $148K sold.
- 29 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2020, up from 12 in Q3 2020.
- Funds reported $12M of Hepion Pharmaceuticals stock for Q4 2020, up 1,515% quarter-over-quarter.
- 23 funds opened new Hepion Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +17 holders.
- The largest Hepion Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $4.48M added.
- The largest Hepion Pharmaceuticals seller in Q4 2020 was Sabby Management, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2020.